Comment on CMS-2026-1256-0002
Vertex PharmaceuticalsOpposeBusiness
Summary: Vertex Pharmaceuticals Incorporated opposes several proposed changes to the New Technology Add-on Payment (NTAP) program, arguing that stricter standards and the repeal of alternative pathways will hinder access to innovative cell and gene therapies. The company advocates for more tailored MS-DRG reforms and extended NTAP periods to ensure sustainable reimbursement for high-cost, low-volume treatments.
Hello, our formal comments are attached.